Optimizing moxidectin dosing for Strongyloides stercoralis infections: Insights from pharmacometric modeling.
Ontology highlight
ABSTRACT: Moxidectin is a frontrunner drug candidate in the treatment of strongyloidiasis. A dose of 8 mg is recommended to treat this indication, which shows a reasonably good efficacy and tolerability profile. Yet, owing to the unique life cycle of Strongyloides stercoralis (S. stercoralis) that entails internal autoinfection, a curative treatment would be desirable. Population-based pharmacometric modeling that would help to identify an ideal dosing strategy are yet lacking. The aims of this study were to (i) explore the exposure-efficacy response relationship of moxidectin in treating S. stercoralis and (ii) evaluate whether moxidectin treatment outcomes in terms of cure rates at baseline as compared to post-treatment could be optimized. Our pharmacodynamic model suggests high predictive power (
SUBMITTER: Hofmann D
PROVIDER: S-EPMC8932710 | biostudies-literature | 2022 Mar
REPOSITORIES: biostudies-literature
ACCESS DATA